The filing reinforces the scientific case for rugonersen ahead of the shareholder vote. Watch for the S-4 effectiveness and proxy mailing, which will set the record date and meeting date. Redemption levels will determine pro forma cash — the sponsor backstop limits downside but does not guarantee low redemptions.
Price Chart
Executive Summary
Research Alliance Corp III (RACC) filed a Rule 425 communication posting Oak Hill Bio's September 2026 corporate presentation on its website. The presentation details the scientific rationale for rugonersen, a Phase 3 antisense oligonucleotide for Angelman syndrome, emphasizing its preclinical and clinical differentiation versus competitors. No changes to deal terms or timeline were disclosed; the filing is promotional in nature ahead of the shareholder vote on the proposed business combination.
Key Financial Metrics
Key Facts
- RACC to combine with Oak Hill Bio at $160 million pre-money equity value.
- Concurrent $100 million financing includes $45 million from RACC Sponsor (RA Capital) and $55 million PIPE.
- Combined company to trade as OAKH on Nasdaq.
- Rugonersen is a Phase 3 ASO for Angelman syndrome, licensed from Roche in February 2025.
- BEACON Phase 3 trial: first patient dosed July 2026, topline data expected early 2029.
- Sponsor backstops up to $75 million of potential redemptions from the trust account.
- Estimated $4-5 billion market opportunity for Angelman syndrome in US and EU5.
- Rugonersen funded through NDA filing in 2H 2029 per the presentation.
Financial Impact
Pre-money equity value of $160 million; $100 million in concurrent financing ($45M SAFE from RA Capital + $55M PIPE); $75 million trust account as of May 31, 2026.
Risk Factors
- Phase 3 BEACON trial (rugonersen may fail to meet primary endpoints; topline data not expected until early 2029.
- Competing ASOs from Ionis (ION582) and Ultragenyx (GTX-102) are also in Phase 3 development.
- Shareholder approval required; significant redemptions could reduce trust cash.
- Pre-clinical comparisons are not head-to-head; clinical differentiation unproven.
- Oak Hill Bio has no approved products, single-product candidate concentration risk.
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 425 Filing (Primary) | 0001193125-26-392963 |
| Document: 0001193125-26-392963-index-headers.html | 0001193125-26-392963 |
| Document: 0001193125-26-392963-index.html | 0001193125-26-392963 |
| Document: 0001193125-26-392963.txt | 0001193125-26-392963 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 7, 2026 20d ago | SC 13G | $10.30 | awaiting T+20 | — | $10.08 (−2.14%) |
Sep 16, 2026 5w ago | 425 | $11.10 $10.15 | ▼ −8.56% | ▼ −10.87% | $10.08 (−9.19%) |
Sep 10, 2026 6w ago | 425 | $11.30 $10.18 | ▼ −9.91% | ▼ −11.78% | $10.08 (−10.80%) |
May 28, 2026 21w ago | 8-K | $10.38 $10.66 | ▲ +2.70% | ▲ +4.49% | $10.08 (−2.89%) |
May 20, 2026 22w ago | 424B4 | $10.28 $10.39 | ▲ +1.07% | ▲ +0.74% | $10.08 (−1.95%) |
May 19, 2026 23w ago | 3 | $10.30 $10.41 | ▲ +1.07% | ▲ +0.33% | $10.08 (−2.14%) |
May 12, 2026 23w ago | S-1/A | — | awaiting T+20 | — | — |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers